Treatment with venetoclax, a Bcl-2-specific inhibitor and FDA-approved leukemia therapy drug, [30–32] also markedly promoted the enucleation of hCB-MNC-derived erythroblasts (Fig. 6J). Here, BCL2 is linked to leukemia.